P0329 - Health-Related Quality of Life in in Adolescents and Adults With Eosinophilic Esophagitis in a Real World Setting in the U.S.

Sunday, October 24, 2021

3:30 PM – 7:00 PM PT

Location: Shoreline Exhibit Hall

Has Audio

Presenting Author(s)

Benjamin D. Gold, MD, FACG

Children’s Center for Digestive Healthcare, LLC, GI Care for Kids
Atlanta, GA, United States

Benjamin D. Gold, MD, FACG¹, Bridgett Goodwin, MS², Kimberly Davis, MS³, Carolyn Sweeney, MPH³, Maria Reynolds, MStat³, Jeanne Jiang, PhD⁴, Tao Fan, PhD, MS⁴, Mena Boules, MD⁴, Nirav K. Desai, MD², David A. Katzka, MD⁵
¹Children’s Center for Digestive Healthcare, LLC, GI Care for Kids, Atlanta, GA; ²Takeda Development Center Americas, Inc., Cambridge, MA; ³RTI Health Solutions, Research Triangle Park, NC; ⁴Takeda Pharmaceuticals USA, Inc., Lexington, MA; ⁵Mayo Clinic, Rochester, MN

Introduction: The disease burden of eosinophilic esophagitis (EoE) can be highly variable, with some patients reporting persistent symptoms that may represent significant daily physical and emotional burdens. The impact of EoE on health-related quality of life (HRQoL) has not been well documented.

Methods: This was a non-interventional, cross-sectional, web-based survey of adolescents (11–17 years old; caregiver-reported) and adults (≥18 years old; self-reported) with EoE in the USA who were recruited from the Campaign Urging Research for Eosinophilic Diseases Foundation (February 2–22, 2021). The impact of EoE on patients’ HRQoL was assessed using patient- and parent proxy-reported outcome instruments.

Results: Overall, 395 participants (caregivers of adolescents, n=211; adults, n=184) completed the survey. Compared with adolescents, a higher proportion of adults reported having problems falling or staying asleep because of their EoE during the past 4 weeks (adolescents, 50.2%; adults, 62.5%); ‘quite a bit’ of interference with normal social activities (adolescents, 10.9%; adults, 20.7%); and feeling worn out ‘all of the time’, ‘most of the time’ or ‘a good bit of the time’ (adolescents, 40.3%; adults, 64.1%). Adolescents reported feeling worried or sad ’sometimes’ (34.1% and 34.1%, respectively), ‘often’ (17.5% and 11.4%, respectively) or ‘almost always’ (6.2% and 1.9%, respectively) over the past 7 days. Adults reported feeling anxious or depressed ’sometimes’ (28.8% and 27.7%, respectively), ‘often’ (26.1% and 13.6%, respectively) or ‘always’ (8.7% and 4.3%, respectively) over the past 7 days. In terms of quantitative scores, the impact of EoE on sleep, social functioning, anxiety and depression was similar in adolescents and adults; however, mean (standard deviation) vitality scores were greater for adolescents versus adults (50.3 [23.7] vs 36.1 [22.0]). Standardized mean derived scores for anxiety and depression in adolescents and adults with EoE were higher than those in the general population (Figure). In total, 81.2% of adolescents and 55.9% of adults missed school or work owing to their EoE over the past 12 months; EoE also had an impact on participants’ other life activities (Table).

Discussion: EoE had a substantial negative impact on multiple HRQoL dimensions, affecting work or schoolwork and social and family life in a high proportion of patients over the past year. Additional studies are needed to further explore HRQoL in patients with EoE.

Figure: Figure. Summary of the impact of EoE on sleep, social functioning, vitality, anxiety and depression in adolescents (11–17 years old; caregiver-reported) and adults (≥ 18 years old; self-reported)

These factors were assessed using patient- and parent proxy-reported outcome instruments: the impact on sleep was evaluated using four questions from the European Health Interview Survey: Developing Common Instruments for Health Surveys (validated in adult populations); the impact on social functioning and vitality was assessed using two items and four items from the Research and Development 36-Item Short Form Health Survey, respectively (validated in adult populations); and the impact on anxiety and depression was assessed using PROMIS Anxiety-8a v1.0 and v2.0, and Depression-8a v1.0 and 6a v2.0, respectively (validated in adult and caregiver [proxy] populations).

*To compare the study estimates with the general population, standardized mean (SD) scores for anxiety and depression in adolescents and adults were compared with a mean (SD) score of 50 (10) for the general population.

EoE, eosinophilic esophagitis; PROMIS, Patient-Reported Outcomes Measurement Information System; SD, standard deviation.

Sheehan Disability Scale question, n (%)	Adolescents (n=211)	Adults (n=184)
The symptoms have disrupted your work/schoolwork	48 (22.7)	42 (22.8)
The symptoms have disrupted your social life/leisure activities	43 (20.4)	49 (26.6)
The symptoms have disrupted your family life/home responsibilities	39 (18.5)	59 (32.1)

Table: Table. Summary of the impact of EoE on work or schoolwork, and social and family life in adolescents (11–17 years old; caregiver-reported) and adults (≥18 years old; self-reported)*

*These were assessed using the Sheehan Disability Scale (three items, each scored from 0 to 10, with a total score of 30; higher scores indicate a greater impact and scores of >5 on any item indicate an impact).

EoE, eosinophilic esophagitis.

Disclosures:

Benjamin Gold: DiaSorin Molecular, LLC – Consultant, Other Financial or Material Support, Participates in continuing medical education activities. Evolve BioSystems, Inc. – Consultant, Other Financial or Material Support, Participates in continuing medical education activities. Johnson & Johnson (Janssen) – Consultant, Other Financial or Material Support, Participates in continuing medical education activities. Mead Johnson Nutrition – Consultant, Stockholder/Ownership Interest (excluding diversified mutual funds), Participates in continuing medical education activities. Nestlé USA – Consultant, Other Financial or Material Support, Participates in continuing medical education activities. Nutricia North America – Consultant, Other Financial or Material Support, Participates in continuing medical education activities. Takeda Pharmaceutical Company Limited – Consultant, Other Financial or Material Support, Participates in continuing medical education activities.

Bridgett Goodwin: Takeda Development Center Americas, Inc. – Employee. Takeda Pharmaceutical Company Limited – Stockholder/Ownership Interest (excluding diversified mutual funds).

Kimberly Davis: RTI Health Solutions – Employee. Takeda Pharmaceutical Company Limited – Grant/Research Support.

Carolyn Sweeney: RTI Health Solutions – Employee. Takeda Pharmaceutical Company Limited – Grant/Research Support.

Maria Reynolds: RTI Health Solutions – Employee. Takeda Pharmaceutical Company Limited – Grant/Research Support.

Jeanne Jiang: Takeda Pharmaceutical Company Limited – Stockholder/Ownership Interest (excluding diversified mutual funds). Takeda Pharmaceuticals USA, Inc. – Employee.

Tao Fan: Takeda Pharmaceutical Company Limited – Stockholder/Ownership Interest (excluding diversified mutual funds). Takeda Pharmaceuticals USA, Inc. – Employee.

Mena Boules: Takeda Pharmaceutical Company Limited – Stockholder/Ownership Interest (excluding diversified mutual funds). Takeda Pharmaceuticals USA, Inc. – Employee.

Nirav Desai: Takeda Development Center Americas, Inc. – Employee. Takeda Pharmaceutical Company Limited – Stockholder/Ownership Interest (excluding diversified mutual funds).

David Katzka: Receptos/Celgene – Consultant. Shire, a Takeda company – Grant/Research Support.

Benjamin D. Gold, MD, FACG¹, Bridgett Goodwin, MS², Kimberly Davis, MS³, Carolyn Sweeney, MPH³, Maria Reynolds, MStat³, Jeanne Jiang, PhD⁴, Tao Fan, PhD, MS⁴, Mena Boules, MD⁴, Nirav K. Desai, MD², David A. Katzka, MD⁵. P0329 - Health-Related Quality of Life in in Adolescents and Adults With Eosinophilic Esophagitis in a Real World Setting in the U.S., ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.